Abstract
Nuclear phosphoinositide-phospholipase C (PI-PLC) beta1 plays a crucial role in the molecular steps that regulate cell proliferation and differentiation in several experimental models, such as myoblasts and hematopoietic cells, via interaction with other important molecular players. Indeed, PI-PLCbeta1 and its related molecules are definitely involved in hematopoiesis, and particularly in drug-induced myeloid or erythroid differentiation. Here, we review the role of nuclear PI-PLCbeta1 signalling in normal hematopoiesis, in pathogenesis and in drug-related induction of hematopoietic differentiation, with particular reference to the current therapy of Myelodysplastic Syndromes (MDS).
Keywords: PI-PLCbeta1, Nucleus, Cell Cycle, Differentiation, Hematopoiesis, MDS.
Current Pharmaceutical Design
Title:Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation
Volume: 22 Issue: 16
Author(s): Sara Mongiorgi, Matilde Y. Follo, Yong Ryoul Yang, Stefano Ratti, Lucia Manzoli, James A. McCubrey, Anna Maria Billi, Pann-Ghill Suh and Lucio Cocco
Affiliation:
Keywords: PI-PLCbeta1, Nucleus, Cell Cycle, Differentiation, Hematopoiesis, MDS.
Abstract: Nuclear phosphoinositide-phospholipase C (PI-PLC) beta1 plays a crucial role in the molecular steps that regulate cell proliferation and differentiation in several experimental models, such as myoblasts and hematopoietic cells, via interaction with other important molecular players. Indeed, PI-PLCbeta1 and its related molecules are definitely involved in hematopoiesis, and particularly in drug-induced myeloid or erythroid differentiation. Here, we review the role of nuclear PI-PLCbeta1 signalling in normal hematopoiesis, in pathogenesis and in drug-related induction of hematopoietic differentiation, with particular reference to the current therapy of Myelodysplastic Syndromes (MDS).
Export Options
About this article
Cite this article as:
Mongiorgi Sara, Y. Follo Matilde, Ryoul Yang Yong, Ratti Stefano, Manzoli Lucia, A. McCubrey James, Maria Billi Anna, Suh Pann-Ghill and Cocco Lucio, Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation, Current Pharmaceutical Design 2016; 22 (16) . https://dx.doi.org/10.2174/1381612822666160226132338
DOI https://dx.doi.org/10.2174/1381612822666160226132338 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets Regulation of Apoptosis and Cell Survival by Resveratrol
Mini-Reviews in Organic Chemistry STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters Therapeutic Potential of Targeting PAK Signaling
Anti-Cancer Agents in Medicinal Chemistry Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Novel Agents in CNS Myeloma Treatment
Central Nervous System Agents in Medicinal Chemistry Mesenchymal Stromal Cells; Role in Tissue Repair, Drug Discovery and Immune Modulation
Current Drug Delivery KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation
Current Medicinal Chemistry Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Contrast Enhanced Sonography for Diagnosis of (Peri-) Splenic Pathology
Current Medical Imaging Hypoxia Inducible Factor Stabilization As a Novel Strategy to Treat Anemia
Current Medicinal Chemistry Adeno-Associated Virus-Mediated Gene Transfer in Hematopoietic Stem/Progenitor Cells as a Therapeutic Tool
Current Gene Therapy Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy
Current Medicinal Chemistry Proteomic Analysis of Aqueous Humor Proteins Associated with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy
Current Proteomics Amphiphilic Cyclodextrin Derivatives for Targeted Drug Delivery to Tumors
Current Topics in Medicinal Chemistry